Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...

Compare Dialysis Centers examined CDC data and other sources to explore kidney disease risk factors and why the condition has ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...

Swiss pharmaceutical giant Novartis is poised to expand its profile in the San Diego area, announcing plans to acquire ...

Currently, doctors sometimes use a drug called spironolactone to treat this condition. It’s a medication that’s been around ...

New Method Predicts Worsening of Chronic Kidney Disease Sep. 12, 2024 — Researchers have developed a new method that could be a significant step in the treatment of chronic kidney disease.

Kidney disease ranges from mild dysfunction treatable with medication to severe cases requiring dialysis or transplant. Acute ...

The latest findings provide reassurance for nephrologists who may be hesitant to prescribe these types of medications.

NGO, Enterprise Group PLC, Volta River Authority (VRA), National Petroleum Authority (NPA), Kalmoni Foundation, Revna ...

Novartis has signed an agreement to acquire US-based Regulus Therapeutics and its oligonucleotide, farabursen.